;PMID: 10759189
;source_file_565.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..46] = [t:0..46]
;1)sentence:[e:51..121] = [t:51..121]
;2)section:[e:125..157] = [t:125..157]
;3)section:[e:161..257] = [t:161..257]
;4)sentence:[e:261..444] = [t:261..444]
;5)sentence:[e:445..563] = [t:445..563]
;6)sentence:[e:564..640] = [t:564..640]
;7)sentence:[e:641..821] = [t:641..821]
;8)sentence:[e:822..914] = [t:822..914]
;9)sentence:[e:915..1080] = [t:915..1080]
;10)sentence:[e:1081..1212] = [t:1081..1212]
;11)sentence:[e:1213..1266] = [t:1213..1266]
;12)sentence:[e:1267..1385] = [t:1267..1385]
;13)sentence:[e:1386..1491] = [t:1386..1491]
;14)sentence:[e:1492..1606] = [t:1492..1606]
;15)sentence:[e:1607..1745] = [t:1607..1745]
;16)sentence:[e:1747..1860] = [t:1747..1860]
;17)section:[e:1864..1909] = [t:1864..1909]

;section 0 Span:0..46
;J Neuropathol Exp Neurol  2000 Apr;59(4):333-7
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..13] Neuropathol) (NNP:[14..17] Exp)
        (NNP:[18..24] Neurol) (CD:[26..30] 2000) (CD:[31..36] Apr;5)
        (CD:[36..37] 9) (NN:[37..38] -LRB-) (NN:[38..39] 4) (NN:[39..40] -RRB-)
        (::[40..41] :) (CD:[41..43] 33) (CD:[43..46] 3-7)))

;sentence 1 Span:51..121
;Nuclear localization and mutation of beta-catenin in medulloblastomas.
;[76..84]:variation-event:"mutation"
;[88..100]:gene-generic:"beta-catenin"
;[104..120]:malignancy:"medulloblastomas"
(SENT
  (NP-HLN
    (NP
      (NP (JJ:[51..58] Nuclear) (NN:[59..71] localization))
      (CC:[72..75] and)
      (NP
        (NP (NN:[76..84] mutation))
        (PP (IN:[85..87] of)
          (NP (NN:[88..100] beta-catenin)))))
    (PP-LOC (IN:[101..103] in)
      (NP (NNS:[104..120] medulloblastomas)))
    (.:[120..121] .)))

;section 2 Span:125..157
;Eberhart CG, Tihan T, Burger PC.
(SEC
  (FRAG (NNP:[125..133] Eberhart) (NNP:[134..136] CG) (,:[136..137] ,)
        (NNP:[138..143] Tihan) (NNP:[144..145] T) (,:[145..146] ,)
        (NNP:[147..153] Burger) (NNP:[154..156] PC) (.:[156..157] .)))

;section 3 Span:161..257
;Department of Pathology, Johns Hopkins University School of Medicine,
;Baltimore,  Maryland, USA.
(SEC
  (FRAG (NNP:[161..171] Department) (IN:[172..174] of)
        (NNP:[175..184] Pathology) (NNP:[184..185] ,) (NNP:[186..191] Johns)
        (NNP:[192..199] Hopkins) (NNP:[200..210] University)
        (NNP:[211..217] School) (IN:[218..220] of) (NNP:[221..229] Medicine)
        (,:[229..230] ,) (NNP:[231..240] Baltimore) (,:[240..241] ,)
        (NNP:[243..251] Maryland) (,:[251..252] ,) (NNP:[253..256] USA)
        (.:[256..257] .)))

;sentence 4 Span:261..444
;The adenomatous polyposis coli (APC) gene, a member of the Wingless/Wnt
;signal  transduction pathway, has been implicated in the development of
;medulloblastomas  in Turcot's syndrome.
;[265..291]:gene-rna:"adenomatous polyposis coli"
;[293..296]:gene-rna:"APC"
;[320..328]:gene-generic:"Wingless"
;[329..332]:gene-generic:"Wnt"
;[405..421]:malignancy:"medulloblastomas"
;[426..443]:malignancy:"Turcot's syndrome"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[261..264] The)
        (NML
          (NML (JJ:[265..276] adenomatous) (NN:[277..286] polyposis)
               (NN:[287..291] coli))
          (NML (-LRB-:[292..293] -LRB-) (NN:[293..296] APC)
               (-RRB-:[296..297] -RRB-)))
        (NN:[298..302] gene))
      (,:[302..303] ,)
      (NP
        (NP (DT:[304..305] a) (NN:[306..312] member))
        (PP (IN:[313..315] of)
          (NP (DT:[316..319] the)
            (NML (JJ:[320..328] Wingless) (SYM:[328..329] /) (NN:[329..332] Wnt))
            (NN:[333..339] signal) (NN:[341..353] transduction)
             (NN:[354..361] pathway)))))
    (,:[361..362] ,)
    (VP (VBZ:[363..366] has)
      (VP (VBN:[367..371] been)
        (VP (VBN:[372..382] implicated)
          (NP-1 (-NONE-:[382..382] *))
          (PP (IN:[383..385] in)
            (NP
              (NP (DT:[386..389] the) (NN:[390..401] development))
              (PP (IN:[402..404] of)
                (NP (NNS:[405..421] medulloblastomas)))
              (PP (IN:[423..425] in)
                (NP
                  (NP (NNP:[426..432] Turcot) (POS:[432..434] 's))
                  (NN:[435..443] syndrome))))))))
    (.:[443..444] .)))

;sentence 5 Span:445..563
;beta-catenin also functions in this highly conserved  signaling pathway and
;is instrumental in growth and development.
;[445..457]:gene-generic:"beta-catenin"
(SENT
  (S
    (NP-SBJ (NN:[445..457] beta-catenin))
    (ADVP (RB:[458..462] also))
    (VP
      (VP (VBZ:[463..472] functions)
        (PP (IN:[473..475] in)
          (NP (DT:[476..480] this)
            (ADJP (RB:[481..487] highly) (JJ:[488..497] conserved))
            (NN:[499..508] signaling) (NN:[509..516] pathway))))
      (CC:[517..520] and)
      (VP (VBZ:[521..523] is)
        (NP-PRD
          (NP (JJ:[524..536] instrumental))
          (PP (IN:[537..539] in)
            (NP (NN:[540..546] growth) (CC:[547..550] and)
                (NN:[551..562] development))))))
    (.:[562..563] .)))

;sentence 6 Span:564..640
;Mutations in  either APC or beta-catenin can stabilize beta-catenin protein.
;[585..588]:gene-rna:"APC"
;[592..604]:gene-rna:"beta-catenin"
;[619..631]:gene-protein:"beta-catenin"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[564..573] Mutations))
      (PP-LOC (IN:[574..576] in)
        (NP (CC:[578..584] either) (NN:[585..588] APC) (CC:[589..591] or)
            (NN:[592..604] beta-catenin))))
    (VP (MD:[605..608] can)
      (VP (VB:[609..618] stabilize)
        (NP (NN:[619..631] beta-catenin) (NN:[632..639] protein))))
    (.:[639..640] .)))

;sentence 7 Span:641..821
;Stabilized  beta-catenin complexes with Tcf/Lef transcription factors and
;moves from the  cytoplasm into the nucleus where it regulates the
;transcription of c-Myc and  other genes.
;[653..665]:gene-protein:"beta-catenin"
;[681..684]:gene-protein:"Tcf"
;[685..688]:gene-protein:"Lef"
;[798..803]:gene-rna:"c-Myc"
(SENT
  (S
    (NP-SBJ (JJ:[641..651] Stabilized) (NN:[653..665] beta-catenin))
    (VP
      (VP (VBZ:[666..675] complexes)
        (PP (IN:[676..680] with)
          (NP
            (NML (NN:[681..684] Tcf) (SYM:[684..685] /) (NN:[685..688] Lef))
            (NN:[689..702] transcription) (NNS:[703..710] factors))))
      (CC:[711..714] and)
      (VP (VBZ:[715..720] moves)
        (PP (IN:[721..725] from)
          (NP (DT:[726..729] the) (NN:[731..740] cytoplasm)))
        (PP (IN:[741..745] into)
          (NP
            (NP (DT:[746..749] the) (NN:[750..757] nucleus))
            (SBAR
              (WHADVP-1 (WRB:[758..763] where))
              (S
                (NP-SBJ (PRP:[764..766] it))
                (VP (VBZ:[767..776] regulates)
                  (NP
                    (NP (DT:[777..780] the) (NN:[781..794] transcription))
                    (PP (IN:[795..797] of)
                      (NP
                        (NP (NN:[798..803] c-Myc))
                        (CC:[804..807] and)
                        (NP (JJ:[809..814] other) (NNS:[815..820] genes)))))
                  (ADVP-LOC-1 (-NONE-:[820..820] *T*)))))))))
    (.:[820..821] .)))

;sentence 8 Span:822..914
;Nuclear localization of beta-catenin therefore implies activation  of the
;signaling pathway.
;[846..858]:gene-protein:"beta-catenin"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[822..829] Nuclear) (NN:[830..842] localization))
      (PP (IN:[843..845] of)
        (NP (NN:[846..858] beta-catenin))))
    (ADVP (RB:[859..868] therefore))
    (VP (VBZ:[869..876] implies)
      (NP
        (NP (NN:[877..887] activation))
        (PP (IN:[889..891] of)
          (NP (DT:[892..895] the) (NN:[896..905] signaling)
              (NN:[906..913] pathway)))))
    (.:[913..914] .)))

;sentence 9 Span:915..1080
;We have analyzed the subcellular localization of  beta-catenin in 51 sporadic
;medulloblastomas and in 1 medulloblastoma arising in  a patient with Turcot's
;syndrome.
;[965..977]:gene-protein:"beta-catenin"
;[984..1009]:malignancy:"sporadic medulloblastomas"
;[1019..1034]:malignancy:"medulloblastoma"
;[1062..1079]:malignancy:"Turcot's syndrome"
(SENT
  (S
    (NP-SBJ (PRP:[915..917] We))
    (VP (VBP:[918..922] have)
      (VP (VBN:[923..931] analyzed)
        (NP
          (NP (DT:[932..935] the) (JJ:[936..947] subcellular)
              (NN:[948..960] localization))
          (PP (IN:[961..963] of)
            (NP (NN:[965..977] beta-catenin))))
        (PP-LOC
          (PP (IN:[978..980] in)
            (NP (CD:[981..983] 51)
               (JJ:[984..992] sporadic) (NNS:[993..1009] medulloblastomas)))
          (CC:[1010..1013] and)
          (PP (IN:[1014..1016] in)
            (NP
              (NP (CD:[1017..1018] 1) (NN:[1019..1034] medulloblastoma))
              (VP (VBG:[1035..1042] arising)
                (PP-LOC (IN:[1043..1045] in)
                  (NP
                    (NP (DT:[1047..1048] a) (NN:[1049..1056] patient))
                    (PP (IN:[1057..1061] with)
                      (NP
                        (NP (NNP:[1062..1068] Turcot) (POS:[1068..1070] 's))
                        (NN:[1071..1079] syndrome)))))))))))
    (.:[1079..1080] .)))

;sentence 10 Span:1081..1212
;Nuclear beta-catenin staining was present in 9  of the sporadic tumors (18%)
;and in the 1 medulloblastoma from a Turcot's  patient.
;[1089..1101]:gene-protein:"beta-catenin"
;[1136..1151]:malignancy:"sporadic tumors"
;[1171..1186]:malignancy:"medulloblastoma"
;[1194..1202]:malignancy:"Turcot's"
(SENT
  (S
    (NP-SBJ (JJ:[1081..1088] Nuclear) (NN:[1089..1101] beta-catenin)
            (NN:[1102..1110] staining))
    (VP (VBD:[1111..1114] was)
      (ADJP-PRD (JJ:[1115..1122] present))
      (PP-LOC
        (PP (IN:[1123..1125] in)
          (NP
            (NP (CD:[1126..1127] 9))
            (PP (IN:[1129..1131] of)
              (NP (DT:[1132..1135] the)
                 (JJ:[1136..1144] sporadic) (NNS:[1145..1151] tumors)))
            (PRN (-LRB-:[1152..1153] -LRB-)
              (NP (CD:[1153..1155] 18) (NN:[1155..1156] %))
              (-RRB-:[1156..1157] -RRB-))))
        (CC:[1158..1161] and)
        (PP (IN:[1162..1164] in)
          (NP
            (NP (DT:[1165..1168] the) (CD:[1169..1170] 1)
                (NN:[1171..1186] medulloblastoma))
            (PP (IN:[1187..1191] from)
              (NP (DT:[1192..1193] a)
                (NML (NNP:[1194..1200] Turcot) (POS:[1200..1202] 's))
                (NN:[1204..1211] patient)))))))
    (.:[1211..1212] .)))

;sentence 11 Span:1213..1266
;The remaining 41 cases did not show nuclear staining.
(SENT
  (S
    (NP-SBJ (DT:[1213..1216] The) (VBG:[1217..1226] remaining)
            (CD:[1227..1229] 41) (NNS:[1230..1235] cases))
    (VP (VBD:[1236..1239] did) (RB:[1240..1243] not)
      (VP (VB:[1244..1248] show)
        (NP (JJ:[1249..1256] nuclear) (NN:[1257..1265] staining))))
    (.:[1265..1266] .)))

;sentence 12 Span:1267..1385
;This confirms  earlier observations that Wingless/Wnt signaling is involved
;in a subset of  sporadic medulloblastomas.
;[1308..1316]:gene-generic:"Wingless"
;[1317..1320]:gene-generic:"Wnt"
;[1359..1384]:malignancy:"sporadic medulloblastomas"
(SENT
  (S
    (NP-SBJ (DT:[1267..1271] This))
    (VP (VBZ:[1272..1280] confirms)
      (NP (JJR:[1282..1289] earlier) (NNS:[1290..1302] observations)
        (SBAR (IN:[1303..1307] that)
          (S
            (NP-SBJ-1
              (NML (JJ:[1308..1316] Wingless) (SYM:[1316..1317] /)
                   (NN:[1317..1320] Wnt))
              (NN:[1321..1330] signaling))
            (VP (VBZ:[1331..1333] is)
              (VP (VBN:[1334..1342] involved)
                (NP-1 (-NONE-:[1342..1342] *))
                (PP-CLR (IN:[1343..1345] in)
                  (NP
                    (NP (DT:[1346..1347] a) (NN:[1348..1354] subset))
                    (PP (IN:[1355..1357] of)
                      (NP (JJ:[1359..1367] sporadic)
                          (NNS:[1368..1384] medulloblastomas)))))))))))
    (.:[1384..1385] .)))

;sentence 13 Span:1386..1491
;We also examined 48 glial and meningeal CNS tumors,  all of which were
;negative for nuclear beta-catenin.
;[1406..1411]:malignancy:"glial"
;[1416..1436]:malignancy:"meningeal CNS tumors"
;[1478..1490]:gene-protein:"beta-catenin"
(SENT
  (S
    (NP-SBJ (PRP:[1386..1388] We))
    (ADVP (RB:[1389..1393] also))
    (VP (VBD:[1394..1402] examined)
      (NP
        (NP (CD:[1403..1405] 48)
          (NML
            (NML
              (NML (JJ:[1406..1411] glial)
                (NML-3 (-NONE-:[1411..1411] *P*)))
              (NML-2 (-NONE-:[1411..1411] *P*)))
            (CC:[1412..1415] and)
            (NML
              (NML-3 (JJ:[1416..1425] meningeal)
                (NML (NN:[1426..1429] CNS)))
              (NML-2 (NNS:[1430..1436] tumors)))))
        (,:[1436..1437] ,)
        (SBAR
          (WHNP-1
            (NP (DT:[1439..1442] all))
            (WHPP (IN:[1443..1445] of)
              (WHNP (WDT:[1446..1451] which))))
          (S
            (NP-SBJ-1 (-NONE-:[1451..1451] *T*))
            (VP (VBD:[1452..1456] were)
              (ADJP-PRD (JJ:[1457..1465] negative)
                (PP (IN:[1466..1469] for)
                  (NP (JJ:[1470..1477] nuclear) (NN:[1478..1490] beta-catenin)))))))))
    (.:[1490..1491] .)))

;sentence 14 Span:1492..1606
;Exon 3 of beta-catenin was  sequenced in 6 of the 9 sporadic medulloblastomas
;with nuclear beta-catenin  staining.
;[1492..1498]:variation-location:"Exon 3"
;[1502..1514]:gene-rna:"beta-catenin"
;[1544..1569]:malignancy:"sporadic medulloblastomas"
;[1583..1595]:gene-protein:"beta-catenin"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[1492..1496] Exon) (CD:[1497..1498] 3))
      (PP (IN:[1499..1501] of)
        (NP (NN:[1502..1514] beta-catenin))))
    (VP (VBD:[1515..1518] was)
      (VP (VBN:[1520..1529] sequenced)
        (NP-1 (-NONE-:[1529..1529] *))
        (PP (IN:[1530..1532] in)
          (NP
            (NP (CD:[1533..1534] 6))
            (PP (IN:[1535..1537] of)
              (NP
                (NP (DT:[1538..1541] the) (CD:[1542..1543] 9)
                   (JJ:[1544..1552] sporadic)
                   (NNS:[1553..1569] medulloblastomas))
                (PP (IN:[1570..1574] with)
                  (NP (JJ:[1575..1582] nuclear) (NN:[1583..1595] beta-catenin)
                      (NN:[1597..1605] staining)))))))))
    (.:[1605..1606] .)))

;sentence 15 Span:1607..1745
;Five of the 6 tumors sequenced had mutations affecting highly  conserved
;beta-catenin phosphorylation sites involved in protein stability.
;[1621..1627]:malignancy:"tumors"
;[1642..1651]:variation-event:"mutations"
;[1680..1692]:gene-generic:"beta-catenin"
;[1727..1734]:gene-protein:"protein"
(SENT
  (S
    (NP-SBJ
      (NP (CD:[1607..1611] Five))
      (PP (IN:[1612..1614] of)
        (NP
          (NP (DT:[1615..1618] the) (CD:[1619..1620] 6)
              (NNS:[1621..1627] tumors))
          (VP (VBN:[1628..1637] sequenced)
            (NP (-NONE-:[1637..1637] *))))))
    (VP (VBD:[1638..1641] had)
      (NP
        (NP (NNS:[1642..1651] mutations))
        (VP (VBG:[1652..1661] affecting)
          (NP
            (NP
              (ADJP (RB:[1662..1668] highly) (JJ:[1670..1679] conserved))
              (NN:[1680..1692] beta-catenin) (NN:[1693..1708] phosphorylation)
               (NNS:[1709..1714] sites))
            (VP (VBN:[1715..1723] involved)
              (NP (-NONE-:[1723..1723] *))
              (PP-CLR (IN:[1724..1726] in)
                (NP (NN:[1727..1734] protein) (NN:[1735..1744] stability))))))))
    (.:[1744..1745] .)))

;sentence 16 Span:1747..1860
;These data suggest a simple immunohistochemical method to screen for 
;beta-catenin mutations in medulloblastomas.
;[1817..1829]:gene-rna:"beta-catenin"
;[1843..1859]:malignancy:"medulloblastomas"
(SENT
  (S
    (NP-SBJ (DT:[1747..1752] These) (NNS:[1753..1757] data))
    (VP (VBP:[1758..1765] suggest)
      (NP (DT:[1766..1767] a) (JJ:[1768..1774] simple)
          (JJ:[1775..1794] immunohistochemical) (NN:[1795..1801] method))
      (S-PRP
        (NP-SBJ (-NONE-:[1801..1801] *))
        (VP (TO:[1802..1804] to)
          (VP (VB:[1805..1811] screen)
            (PP (IN:[1812..1815] for)
              (NP (NN:[1817..1829] beta-catenin) (NNS:[1830..1839] mutations)))
            (PP-LOC (IN:[1840..1842] in)
              (NP (NNS:[1843..1859] medulloblastomas)))))))
    (.:[1859..1860] .)))

;section 17 Span:1864..1909
;PMID: 10759189 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1864..1868] PMID) (::[1868..1869] :) (CD:[1870..1878] 10759189)
        (NN:[1879..1880] -LSB-) (NNP:[1880..1886] PubMed) (::[1887..1888] -)
        (NN:[1889..1896] indexed) (IN:[1897..1900] for)
        (NNP:[1901..1909] MEDLINE-RSB-)))
